DIM
CNST

DC Investments Management’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

DC Investments Management’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-52,174
Closed -$351K – 335
2018
Q3 		$351K Buy
+52,174
New +$497K 0.24% 248

Other funds holding CNST

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DC Investments Management's CNST Position: Q4 2018 in Review

DC Investments Management sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q4 2018, closing a stake of 52,174 shares — an estimated $351K sold.

DC Investments Management first reported a position in CNST in Q3 2018 and held it in 1 quarter. The position peaked at $351K in Q3 2018. 37 funds tracked by Wall St. Rank hold CNST as of Q4 2018.

  • DC Investments Management reported no remaining Constellation Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • DC Investments Management sold 52,174 Constellation Pharmaceuticals, Inc. shares in Q4 2018, an estimated $351K.
  • DC Investments Management first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
  • DC Investments Management's Constellation Pharmaceuticals, Inc. position peaked at $351K in Q3 2018.
  • 37 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q4 2018.

Based on DC Investments Management's 13F filing for Q4 2018, filed 8 Feb 2019.